The increase in the development of arterial hypertension (AH), as the main modifiable risk factor for the development of acute and chronic cerebral circulatory insufficiency, often leading to a progressive decrease in cognitive status and physical activity, requires early detection and effective pathogenetic therapy. The breadth of therapeutic effects of the drug Mexidol (ethylmethylhydroxypyridine succinate) due to the multifactorial nature of its pathogenetic effects contributes to its widespread use. The safe profile of Mexidol use and the absence of drug interaction makes it relevant in the complex treatment of patients with cardiovascular diseases.